Clinical Trials
30 trialsTesting Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
CAPRI
University of Pennsylvania
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
LOTOS
AstraZeneca
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
ATARI
Institute of Cancer Research, United Kingdom
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
AUSTRAL
Mario Negri Institute for Pharmacological Research
HUDSON
AstraZeneca
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
PHOENIX
Institute of Cancer Research, United Kingdom
MONETTE
AstraZeneca
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
PIONeeR
Assistance Publique Hopitaux De Marseille
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
SUKSES-N4
Samsung Medical Center
OLAPCO
Yale University
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
DUETTE
AstraZeneca
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
Samsung Medical Center
plasmaMATCH
Institute of Cancer Research, United Kingdom